Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

77 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy.
Gradishar WJ, Yardley DA, Layman R, Sparano JA, Chuang E, Northfelt DW, Schwartz GN, Youssoufian H, Tang S, Novosiadly R, Forest A, Nguyen TS, Cosaert J, Grebennik D, Haluska P. Gradishar WJ, et al. Clin Cancer Res. 2016 Jan 15;22(2):301-9. doi: 10.1158/1078-0432.CCR-15-0588. Epub 2015 Aug 31. Clin Cancer Res. 2016. PMID: 26324738 Free PMC article. Clinical Trial.
Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.
Hicks M, Macrae ER, Abdel-Rasoul M, Layman R, Friedman S, Querry J, Lustberg M, Ramaswamy B, Mrozek E, Shapiro C, Wesolowski R. Hicks M, et al. Oncologist. 2015 Apr;20(4):337-43. doi: 10.1634/theoncologist.2014-0334. Epub 2015 Mar 2. Oncologist. 2015. PMID: 25732265 Free PMC article.
Breast Cancer Risk Reduction, Version 2.2015.
Bevers TB, Ward JH, Arun BK, Colditz GA, Cowan KH, Daly MB, Garber JE, Gemignani ML, Gradishar WJ, Jordan JA, Korde LA, Kounalakis N, Krontiras H, Kumar S, Kurian A, Laronga C, Layman RM, Loftus LS, Mahoney MC, Merajver SD, Meszoely IM, Mortimer J, Newman L, Pritchard E, Pruthi S, Seewaldt V, Specht MC, Visvanathan K, Wallace A, Bergman MA, Kumar R. Bevers TB, et al. Among authors: layman rm. J Natl Compr Canc Netw. 2015 Jul;13(7):880-915. doi: 10.6004/jnccn.2015.0105. J Natl Compr Canc Netw. 2015. PMID: 26150582
Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors.
Schott AF, Landis MD, Dontu G, Griffith KA, Layman RM, Krop I, Paskett LA, Wong H, Dobrolecki LE, Lewis MT, Froehlich AM, Paranilam J, Hayes DF, Wicha MS, Chang JC. Schott AF, et al. Among authors: layman rm. Clin Cancer Res. 2013 Mar 15;19(6):1512-24. doi: 10.1158/1078-0432.CCR-11-3326. Epub 2013 Jan 22. Clin Cancer Res. 2013. PMID: 23340294 Free PMC article. Clinical Trial.
Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients.
Lustberg MB, Balasubramanian P, Miller B, Garcia-Villa A, Deighan C, Wu Y, Carothers S, Berger M, Ramaswamy B, Macrae ER, Wesolowski R, Layman RM, Mrozek E, Pan X, Summers TA, Shapiro CL, Chalmers JJ. Lustberg MB, et al. Among authors: layman rm. Breast Cancer Res. 2014 Mar 6;16(2):R23. doi: 10.1186/bcr3622. Breast Cancer Res. 2014. PMID: 24602188 Free PMC article.
Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancer.
Mrózek E, Layman R, Ramaswamy B, Lustberg M, Vecchione A, Knopp MV, Shapiro CL. Mrózek E, et al. Clin Breast Cancer. 2014 Aug;14(4):228-34. doi: 10.1016/j.clbc.2014.02.005. Epub 2014 Feb 20. Clin Breast Cancer. 2014. PMID: 24703985 Free PMC article. Clinical Trial.
77 results